We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
RANDOX LABORATORIES

Download Mobile App




Wearable Rapid Gas Analyzer Could Detect Illness Immediately

By LabMedica International staff writers
Posted on 08 Aug 2022
Print article
Image: Associate Professor Yuze “Alice” Sun is creating a wearable device for rapid gas analysis (Photo courtesy of The University of Texas at Arlington)
Image: Associate Professor Yuze “Alice” Sun is creating a wearable device for rapid gas analysis (Photo courtesy of The University of Texas at Arlington)

Advancements in micro-gas chromatography in the past 20 years have demonstrated great potential for the development of powerful portable gas analysis devices. But it remains a challenge to achieve efficient separation and rapid detection for effective gas analysis in a highly integrated and cost-effective platform, as well as in a mobile device. Now, researchers are creating a portable, wearable device for rapid gas analysis that could detect illness immediately.

The device being created by electrical engineering researchers at The University of Texas at Arlington (Arlington, TX, USA) will play an important role in health care, among other sectors. The project will create technology to transform a powerful gas analysis instrument traditionally used in research labs into portable and wearable devices that are easily accepted and accessible by the public. The project has received a USD 550,000 National Science Foundation (NSF) grant from the Partnerships for Innovation–Research Partnerships program, which aims to take devices developed in the laboratory to the marketplace more quickly.

The vast applications could propel the device to the marketplace more quickly. In health care, the device could analyze a person’s breath samples to find chemical markers that are specifically linked to infections, cancers and other health conditions. In turn, that could lead to a convenient and rapid health screening and monitoring tool to be used at home.

“The key to the project is system-level integration, including creating new micro-gas chromatography architecture and using photonic integrated circuits to achieve rapid and comprehensive volatile organic compounds gas analysis,” said Yuze “Alice” Sun, an associate professor in the Department of Electrical Engineering, who is the principal investigator on the project.

“Not only does the project have the potential of improving our lives, but it could take up so much less space than current chromatography analysis machines,” said Diane Huffaker, chair and professor of electrical engineering. “This could save an enormous amount of testing time, too.”

Related Links:
The University of Texas at Arlington 

New
Platinum Member
Flu SARS-CoV-2 Combo Test
OSOM® Flu SARS-CoV-2 Combo Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Complement 3 (C3) Test
GPP-100 C3 Kit
New
Gold Member
Dengue Virus Test
LINEAR Dengue-CHIK

Print article
77 ELEKTRONIKA

Channels

Clinical Chemistry

view channel
Image: PhD student and first author Tarek Eissa has analyzed thousands of molecular fingerprints (Photo courtesy of Thorsten Naeser / MPQ / Attoworld)

Screening Tool Detects Multiple Health Conditions from Single Blood Drop

Infrared spectroscopy, a method using infrared light to study the molecular composition of substances, has been a foundational tool in chemistry for decades, functioning similarly to a molecular fingerprinting... Read more

Molecular Diagnostics

view channel
Image: Researchers have found the first evidence of testing for the alpha-synuclein protein in blood samples via seed amplification assay (Photo courtesy of Shutterstock)

Blood Test to Detect Alpha-Synuclein Protein Could Revolutionize Parkinson's Disease Diagnostics

Currently, Parkinson's disease (PD) is identified through clinical diagnosis, typically at a later stage in the disease's progression. There is a pressing need for an objective and quantifiable biomarker... Read more

Hematology

view channel
Image: The Truvian diagnostic platform combines clinical chemistry, immunoassay and hematology testing in a single run (Photo courtesy of Truvian Health)

Automated Benchtop System to Bring Blood Testing To Anyone, Anywhere

Almost all medical decisions are dependent upon laboratory test results, which are essential for disease prevention and the management of chronic illnesses. However, routine blood testing remains limited worldwide.... Read more

Immunology

view channel
Image: The blood test measures lymphocytes  to guide the use of multiple myeloma immunotherapy (Photo courtesy of 123RF)

Simple Blood Test Identifies Multiple Myeloma Patients Likely to Benefit from CAR-T Immunotherapy

Multiple myeloma, a type of blood cancer originating from plasma cells in the bone marrow, sees almost all patients experiencing a relapse at some stage. This means that the cancer returns even after initially... Read more

Microbiology

view channel
Image: Ultra-Rapid Antimicrobial Susceptibility Testing (uRAST) revolutionizing traditional antibiotic susceptibility testing (Photo courtesy of Seoul National University)

Ultra-Rapid Culture-Free Sepsis Test Reduces Testing Time from Days to Hours

Sepsis, a critical emergency condition, results from an overactive inflammatory response to pathogens like bacteria or fungi in the blood, leading to organ damage and the possibility of sudden death.... Read more

Pathology

view channel
Image: The AI model can distinguish different stages of DCIS from inexpensive and readily available breast tissue images (Photo courtesy of David A. Litman/Shutterstock)

AI Model Identifies Breast Tumor Stages Likely To Progress to Invasive Cancer

Ductal carcinoma in situ (DCIS) is a non-invasive type of tumor that can sometimes progress to a more lethal form of breast cancer and represents about 25% of all breast cancer cases. Between 30% and 50%... Read more

Industry

view channel
Image: Beckman Coulter will utilize the ALZpath pTau217 antibody to detect key biomarker for Alzheimer\'s disease on its DxI 9000 immunoassay analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter Licenses Alzpath's Proprietary P-tau 217 Antibody to Develop Alzheimer's Blood Test

Cognitive assessments have traditionally been the primary method for diagnosing Alzheimer’s disease, but this approach has its limitations as symptoms become apparent only after significant brain changes... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.